Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[In Process Citation]

Brock, Pohl

    Arzneimittel-Forschung
    |December 6, 2000
    PubMed
    Summary
    This summary is machine-generated.

    German oncological research has a rich history, developing key alkylating cytotoxic agents like cyclophosphamide and ifosfamide. The introduction of mesna improved therapy safety and selectivity for cancer treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of the fungicide carbendazim in freshwater microcosms. I. Water quality, breakdown of particulate organic matter and responses of macroinvertebrates.

    Aquatic toxicology (Amsterdam, Netherlands)·2001
    Same author

    Impact of the fungicide carbendazim in freshwater microcosms. II. Zooplankton, primary producers and final conclusions.

    Aquatic toxicology (Amsterdam, Netherlands)·2001
    Same author

    Low temperature acoustic properties of amorphous silica and the tunneling model

    Physical review letters·2000
    Same author

    Towards single-particle spectroscopy of small metal clusters

    Physical review letters·2000
    Same author

    Stream Invertebrate Communities, Water Quality, and Land-Use Patterns in an Agricultural Drainage Basin of Northeastern Nebraska, USA.

    Environmental management·2000
    Same author

    Absolute configurations of Emycin D, E and F; mimicry of centrosymmetric space groups by mixtures of chiral stereoisomers.

    Acta crystallographica. Section B, Structural science·2000
    Same journal

    Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

    Arzneimittel-Forschung·2013
    Same journal

    Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

    Arzneimittel-Forschung·2013
    Same journal

    Leave-one-out procedure in the validation of elimination rate constant analysis.

    Arzneimittel-Forschung·2012
    Same journal

    Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

    Arzneimittel-Forschung·2012
    Same journal

    Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

    Arzneimittel-Forschung·2012
    Same journal

    Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

    Arzneimittel-Forschung·2012
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Medical History

    Background:

    • Oncological therapeutic agent development is complex, costly, and time-consuming, with significant contributions from academic and public research institutions.
    • Increasing regulatory demands since 1960 have amplified development timelines and costs in cancer drug discovery.
    • German oncological research, initiated post-WWII, initially focused on ethyleneimino compounds before shifting to alkylating agents.

    Purpose of the Study:

    • To provide a historical overview of oncological therapeutic agent development in Germany.
    • To highlight key milestones and discoveries in German cancer research, particularly in alkylating agents.
    • To discuss the evolution of cancer therapies and ongoing research directions.

    Main Methods:

    Related Experiment Videos

  • Historical review of oncological research and drug development in Germany.
  • Analysis of key therapeutic agents, their development, and impact.
  • Examination of regulatory influences on drug development costs and timelines.

    • Main Results:

    • Development of significant alkylating cytotoxic agents, including cyclophosphamide, ifosfamide, and trofosfamide, by Asta-Werke.
    • Introduction of mesna for organospecific detoxification, enhancing the safety and selectivity of oxazaophosphorine therapy.
    • Ongoing research into novel alkylating agents and new therapeutic principles like hormonal agents.

    Conclusions:

    • German institutions have played a pivotal role in developing foundational cancer therapies, particularly alkylating agents.
    • The development of supportive agents like mesna has significantly improved patient outcomes and treatment safety.
    • Continued innovation in oncological research, including new drug classes, is crucial for advancing cancer treatment.